Xi Liu
Oprichter bij BEIJING STRONG BIOTECHNOLOGIES,INC.
Vermogen: 159 M $ op 31-05-2024
Actieve functies van Xi Liu
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| BEIJING STRONG BIOTECHNOLOGIES,INC. | Directeur/Bestuurslid | 29-03-2001 | - |
| Algemeen Directeur | 16-03-2011 | - | |
| Oprichter | 29-03-2001 | - | |
Fuzhou Maixin Biotech Co., Ltd.
 Fuzhou Maixin Biotech Co., Ltd. Medical/Nursing ServicesHealth Services Part of Beijing Strong Biotechnologies, Inc., Fuzhou Maixin Biotech Co., Ltd. engages in the production, research & development, and sales of tissue-based diagnostics, specifically IHC antibodies, reagents, and the automation of IHC and ISH. The company is based in Fuzhou, China. Fuzhou Maixin Biotech Co. was acquired by Fuzhou Maixin Biotech Co. Ltd. /Private Group/ on September 30, 2020 for $255.21 million. The Chinese company was founded in 1993. The CEO is Xiao Ya Wang. | Directeur/Bestuurslid | 30-09-2020 | - |
Loopbaan van Xi Liu
Opleiding van Xi Liu
| Harbin Engineering University | Graduate Degree |
| Institute of Automation Chinese Academy of Sciences | Doctorate Degree |
Statistieken
Internationaal
| China | 5 |
Operationeel
| Director/Board Member | 2 |
| Chief Executive Officer | 1 |
| Founder | 1 |
Sectoraal
| Consumer Services | 3 |
| Health Services | 2 |
| Health Technology | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| BEIJING STRONG BIOTECHNOLOGIES,INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Fuzhou Maixin Biotech Co., Ltd.
Fuzhou Maixin Biotech Co., Ltd. Medical/Nursing ServicesHealth Services Part of Beijing Strong Biotechnologies, Inc., Fuzhou Maixin Biotech Co., Ltd. engages in the production, research & development, and sales of tissue-based diagnostics, specifically IHC antibodies, reagents, and the automation of IHC and ISH. The company is based in Fuzhou, China. Fuzhou Maixin Biotech Co. was acquired by Fuzhou Maixin Biotech Co. Ltd. /Private Group/ on September 30, 2020 for $255.21 million. The Chinese company was founded in 1993. The CEO is Xiao Ya Wang. | Health Services |
